Tillotts’ R&D work is conducted from Tillotts’ headquarters located in Rheinfelden, Switzerland. We are committed to growing an innovative and well-balanced product portfolio both from in-house developments and through in-licensing and selective acquisitions. With our in-house expertise and network of research partners, we are committed to developing new and more advanced treatments that can help gastroenterologists improve patient care.
We partner and collaborate with a number of progressive companies and societies, including the International Organization for the Study of Inflammatory Bowel Disease (IOIBD) and the European Crohn’s and Colitis Organisation (ECCO). Tillotts also supports external academic collaborations to expand our scientific know-how and Intellectual Property (IP) platform.
For more information, please take a look at our pipeline of development and life-cycle management programmes.